- Home
- AMAL vs RAPP Comparison
AMAL vs RAPP Comparison
Compare AMAL & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | AMAL | RAPP |
|---|---|---|
| Founded | 1923 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AMAL | RAPP |
|---|---|---|
| Price | $46.78 | $29.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $55.33 | ★ $62.71 |
| AVG Volume (30 Days) | 204.0K | ★ 405.9K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ 1.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.45 | N/A |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $23.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.03 | $23.75 |
| 52 Week High | $51.59 | $52.93 |
Technical Indicators
Market Signals| Indicator | AMAL | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 28.49 |
| Support Level | $46.34 | $25.90 |
| Resistance Level | $48.50 | $28.42 |
| Average True Range (ATR) | 1.05 | 1.57 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 44.54 | 17.93 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.